letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...6263646566676869707172...100101»
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Clinical, Journal:  Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. (Pubmed Central) -  Apr 15, 2020   
    Letrozole may be used to improve sperm parameters in infertile men with low serum testosterone to estradiol ratio. Ribociclib, when added to endocrine therapy, significantly improves PFS and has manageable toxicity in premenopausal/perimenopausal and postmenopausal women with HR+/HER2- advanced breast cancer.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Review, Journal:  Pathophysiological changes in experimental polycystic ovary syndrome in female albino rats: Using either hemin or L-arginine. (Pubmed Central) -  Apr 10, 2020   
    Thus, this study aims to examine the possible individual prophylactic effects of gasotransmitters, hemin, or L-arginine in letrozole-induced PCOS...Our results proved that either hemin or L-arginine administration could improve the oxidative state, the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO rats, which was confirmed by a histopathological examination of the rats' ovaries. In conclusion, either hemin or L-arginine had protective effects against PCOS with better pathophysiological changes with hemin.
  • ||||||||||  letrozole / Generic mfg.
    New P3 trial:  Letrozole in Tubal Ectopic Pregnancy (clinicaltrials.gov) -  Apr 9, 2020   
    P3,  N=214, Not yet recruiting, 
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Metastases:  CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Apr 2, 2020   
    P2,  N=204, Active, not recruiting, 
    Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021 Not yet recruiting --> Active, not recruiting
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Chronic aromatase inhibition increases ventral hippocampal neurogenesis in middle-aged female mice. (Pubmed Central) -  Apr 1, 2020   
    We found that letrozole increased DCX and Ki67 expression and maturation in the dentate gyrus, but had no significant effect on depressive-like behavior. Our findings suggest that a reduction in estrogens in middle-aged females increases hippocampal neurogenesis without any adverse impact on depressive-like behavior; as such, this furthers our understanding of how estrogens modulate neurogenesis, and to the rationale for the utilization of letrozole in the clinical management of breast cancer.
  • ||||||||||  letrozole / Generic mfg.
    Increased In Vivo Pulsatile LH Secretion and Hypothalamic Kisspeptin, NKB, and Dynorphin RNA Levels in a PCOS-Like Mouse Model (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4092;    
    Females given constant, long-term letrozole to reduce aromatase activity demonstrate PCOS-like phenotypes, including polycystic ovaries, anovulation, elevated circulating testosterone, and increased LH...Our findings demonstrate that LET mice, like PCOS women, have markedly elevated LH pulsatility which likely drives increased ovarian androgen secretion. Increased arcuate kisspeptin and NKB levels may be fundamental contributors to the enhanced stimulation of LH pulse secretion in this PCOS-like condition, and perhaps, in some PCOS women.
  • ||||||||||  letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
    A Prospective Non-surgical Treatment for Inguinal Hernias (ENDOExpo, Booth 2114) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_3829;    
    Ablation of estrogen production or its signaling not only completely prevents this phenotype but also reverses mild to moderate-sized hernias. Our findings pave the pathway for developing the first potential preventive and therapeutic pharmacological approach for combating recurrent inguinal hernias in elderly men through modulation of estrogen signaling in abdominal muscle tissue.
  • ||||||||||  Afinitor (everolimus) / Novartis, Kisqali (ribociclib) / Novartis
    Review, Journal:  Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) -  Mar 29, 2020   
    The main clinical effectiveness evidence was obtained from the MONALEESA-2 trial, a randomised controlled trial comparing ribociclib plus letrozole with placebo plus letrozole...Patient-level data from the BOLERO-2 trial, evaluating the addition of everolimus to exemestane in the second-line treatment of postmenopausal HR-positive advanced breast cancer, were used to inform the length of progression-free survival during the second line...After two appraisal committee meetings and a revised base case submitted by the company (including a second enhanced patient access scheme discount), the committee concluded that taking into account the uncertainties in the calculation of the cost effectiveness, there were plausible cost-effectiveness estimates broadly in the range that could be considered as a cost-effective use of National Health Service resources. Therefore, ribociclib was recommended as a treatment option for the first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, contingent on the company providing ribociclib with the discount agreed in the second enhanced patient access scheme.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  Male axillary accessory breast cancer: A case report. (Pubmed Central) -  Mar 25, 2020   
    Axillary accessory breast cancer in males is extremely rare, with no conspicuous and typical clinical presentations, which leads to inevitable neglect by clinicians. Therefore, there is significant necessity for clinicians to be cautious with this type of disease.
  • ||||||||||  letrozole / Generic mfg., Tamoxis (tamoxifen) / Bioprofarma
    Journal:  Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer. (Pubmed Central) -  Mar 25, 2020   
    Three months after starting letrozole, she presented with sudden fever and exuberant and painful erythematous skin papules and plaques on her upper body...She resumed adjuvant treatment with tamoxifen, without symptom recurrence...Aromatase inhibitors are widely used in the treatment of breast cancer and, though infrequent, it is important to recognize possible cutaneous adverse events.Sweet's syndrome is a rare but troublesome condition. Prompt recognition and management are crucial to alleviate symptoms.Drug-induced Sweet's syndrome associated with aromatase inhibitors has not been previously reported and should be considered when evaluating treatment toxicities.
  • ||||||||||  letrozole / Generic mfg.
    New P4 trial:  Hormone Secretion in Transgender Males (clinicaltrials.gov) -  Mar 24, 2020   
    P4,  N=26, Not yet recruiting, 
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome (clinicaltrials.gov) -  Mar 24, 2020   
    P3,  N=150, Recruiting, 
    Recruiting --> Suspended Trial completion date: Feb 2020 --> Aug 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Detection of estradiol in rat brain tissues: Contribution of local versus systemic production. (Pubmed Central) -  Mar 20, 2020   
    Studies also demonstrated that the differences between serum and brain levels of E2 can be eliminated by letrozole (ARO inhibitor) treatment, which indicates that the differences are due to local ARO activity. Collectively the results provide a detailed analysis of brain region-specific E2 concentrations in OVX, E2-, and T-treated rats and demonstrate the degree to which these concentrations are ARO-dependent.